

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent 6,251,910

GUILE et al.

Atty. Ref.: 3764-207; Confirmation No. 7945

Appl. No. 09/155023

TC/A.U. 1624; Issued: June 26, 2001

Filed: September 21, 1998

Examiner: McKenzie, T.C.

For: 1,2,3-TRIAZOLO[4,5-D]PYRIMIDINES AS P2T RECEPTOR ANTAGONISTS

\* \* \* \* \*

Mail Stop Hatch-Waxman PTE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

POWER OF ATTORNEY

AstraZeneca UK Limited, the assignee of the entire legal right, title and interest in US Patent 6,251,910, hereby appoints the attorneys of **Customer Number 23117** individually and collectively its agent to prosecute the present application for patent term extension, and to transact all business in the Patent and Trademark Office in connection therewith.

Please direct correspondence for this application to the address associated with **Customer Number 23117**. Please direct telephone calls to Leonard C. Mitchard at (703) 816-4005.

**Certificate Under 37 C.F.R. §3.73(b)**

AstraZeneca UK Limited, a corporation having a place of business at 2 Kingdom Street, London UK W2 6BD, hereby states that it is the assignee of the entire legal right, title and interest in the patent identified above by virtue of an assignment from the inventors to Astra Pharmaceuticals Ltd. recorded at the United States Patent Office on September 21, 1998 at reel 009923, frame 0502, an assignment from Astra Pharmaceuticals Ltd. to AstraZeneca UK Limited recorded at the United States Patent Office on February 28, 2001 at reel 011607, frame 0100, and an assignment from Astra AB and AstraZeneca Pharmaceuticals Limited to AstraZeneca UK Limited recorded at the United States Patent Office on March 30, 2001 at reel 011705, frame 0156.

The undersigned (whose title is typed below) is empowered to sign this statement on behalf of the assignee.

**AstraZeneca UK Limited**

07 SEPTEMBER 2011

Date

By:



Name: DR. ALLEN F GILES

Title: AUTHORIZED REPRESENTATIVE